| P2093 | author name string | Masafumi Ikeda | |
| | Takuji Okusaka | |
| | Hiroshi Ishii | |
| | Chigusa Morizane | |
| | Junji Furuse | |
| | Makoto Ueno | |
| P2860 | cites work | JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan | Q26797521 |
| | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression | Q27485914 |
| | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 |
| | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis | Q46355180 |
| | SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 |
| | Hepatic Arterial Infusion Therapy with a Fine Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis | Q53279945 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 |
| | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment | Q28079378 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 |
| | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases | Q33344056 |
| | Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma | Q33379364 |
| | Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis | Q33389786 |
| | Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma | Q33390589 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial | Q33423800 |
| | Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil | Q33428936 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 |
| | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Q36104399 |
| | National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma. | Q37000692 |
| | Molecular targeted therapies in hepatocellular carcinoma | Q37003665 |
| | Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma | Q37015632 |
| | Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan | Q37214365 |
| | Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial | Q37387978 |
| | Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma | Q37710134 |
| | Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon | Q37771190 |
| | Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 |
| | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. | Q38062681 |
| | Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. | Q38176242 |
| | Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. | Q38505900 |
| | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial | Q38789875 |
| | FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma | Q39297937 |
| | Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. | Q39863380 |
| | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 |
| | Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion | Q40339271 |
| | Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma | Q41187204 |
| | Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future | Q42343451 |
| | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study | Q42606277 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P577 | publication date | 2017-12-15 | |
| P1433 | published in | Japanese Journal of Clinical Oncology | Q2231629 |
| P1476 | title | Chemotherapy for hepatocellular carcinoma: current status and future perspectives | |